Drug · DIN 02419483
REMSIMA
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since October 28, 2025; first marketed September 18, 2014.
- Drug Identification Number (DIN)
- 02419483
- Company (DIN owner)
- Celltrion Inc.Incheon, Korea, Republic Of
- Schedule
- Prescription; Schedule D
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Infliximab L04AB02
- Class
- Human
- Record last updated
- November 10, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INFLIXIMAB | 100 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 28, 2024: NOC 33539New Drug Submission (NDS) · Administrative / ¿ Change in Product Ownership
- January 15, 2014: NOC 15125New Drug Submission (NDS)